PREPARE trial: A randomized phas III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer-outcome on prognosis

Annals of Oncology

Volumn 22, Issue 9, 2011, Pages 1999-2006

  Untch, M ^a   von Minckwitz, G ^b   Konecny, G E ^c   Conrad, U ^d   Fett, W ^e   Kurzeder, C ^f   Luck H J ^g   Stickeler, E ^h   Urbaczyk, H ⁱ   Liedtke, B ^j   Beckmann, M W ^k   Salat, C ^l   Harbeck, N ^m   Muller V ⁿ   Schmidt, M ^o   Hasmuller S ^p   Lenhard, M ^p   Nekljudova, V ^b   Lebeau, A ⁿ   Loibl, S ^b   Fasching, P A ^k   more..

^a HELIOS KLINIKUM BERLIN BUCH   (Germany)

^b GERMAN BREAST GROUP   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d St Barbara Hospital   (Germany)

^e Hematologic/Oncologic Practice   (Germany)

^f UNIVERSITY HOSPITAL ULM   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ KLINIKUM KASSEL   (Germany)

^j Krankenhaus Bergisch   (Germany)

^k UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^l Hematology Oncology Center   (Germany)

^m TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁿ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^o UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^p LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

more..

Author keywords

Darbepoetin alfa; Neoadjuvant dose dense chemotherapy; Neoadjuvant dose intensified therapy; Primary breast cancer

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; ERYTHROPOIETIN; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PACLITAXEL; PATIENT COMPLIANCE; PREOPERATIVE CARE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052401850     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq713     Document Type: Article

References (13)

1. Bear HD, Anderson S, Smith RE et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer. National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24: 2019-2027.
2. Untch M, Möbus V, Kuhn W et al. Intensive dose-dense chemotherapy compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 2009; 27: 1-9.
3. Untch M, Fasching PA, Konecny GE et al. Prepare trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel +/2 darbepoetin alfa in primary breast cancer - results at the time of surgery. Ann Oncol 2011; 22: 1988-1998.
4. Kaufmann M, Eiermann W, Schütte M et al. Long-term results from the neoadjuvant GeparDuo trial: a randomized, multicenter, open phase III study comparing a dose-intensified 8-week schedule of doxorubicin hydrochloride and docetaxel (ADoc) with a sequential 24-week schedule of doxorubicin hydrochloride/cyclophosphamide followed by docetaxel (AC-Doc) regimen as preoperative therapy (NACT) in patients (pts) with operable breast cancer (BC). J Clin Oncol 2010; 28: 15S (Abstr 537).
5. von Minckwitz G, Kaufmann M, Kümmel S et al. Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +/- trastuzumab containing chemotherapy. Cancer Res 2009; 69 (Suppl): #79.
6. von Minckwitz G, Untch M, Nüesch E et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011; 125: 145-156.
7. Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373: 1532-1542.
8. Möbus V, Jackisch C, Lück HJ et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer (4+ LN): mature results of an AGO-phase-III study. J Clin Oncol 2010; 28: 2874-2880.
9. Leyland-Jones B, Semiglazov V, Pawlicki M. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23: 5960-5972.
10. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98: 708-714.
11. Ludwig H, Crawford J, Osterborg A et al. Pooled analysis of individual patient-level data from all randomized, double blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009; 27: 2838-2847.
12. Untch M, Stoeckl D, Konecny G et al. A multicenter phase II study of preoperative epirubicin, cyclophosphamide (EC) followed by paclitaxel (P) plus trastuzumab (T) in Her2 positive primary breast cancer. San Antonio Breast Cancer Symposium 2005 (Abstr 1064).
13. Untch M, Fasching AP, Konecny GE et al. Pathological complete response after neoadjuvant chemotherapy + trastuzumab treatment predicts survival and detects a patient subgroup at high need for improvement of anti-HER2 therapy. Three year median follow up data of the TECHNO trial. J Clin Oncol 2011; in press.